

Dana Horáková

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8097996/publications.pdf>

Version: 2024-02-01

146
papers

6,589
citations

70961

41
h-index

74018

75
g-index

150
all docs

150
docs citations

150
times ranked

5919
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. <i>European Journal of Neurology</i> , 2022, 29, 1082-1090.	1.7	11
2	The clinical and paraclinical correlates of employment status in multiple sclerosis. <i>Neurological Sciences</i> , 2022, 43, 1911-1920.	0.9	4
3	Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103391.	0.9	7
4	Pregnancy-induced brain magnetic resonance imaging changes in women with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 1446-1456.	1.7	7
5	Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up. <i>Frontiers in Immunology</i> , 2022, 13, 818325.	2.2	5
6	Multiple Sclerosis Relapses Following Cessation of Fingolimod. <i>Clinical Drug Investigation</i> , 2022, 42, 355-364.	1.1	8
7	Time course of lesion-induced atrophy in multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 4478-4487.	1.8	3
8	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210845.	1.4	2
9	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Pharmacoeconomics</i> , 2022, 40, 323-339.	1.7	3
10	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.5	12
11	Periventricular gradient of T1 tissue alterations in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2022, 34, 103009.	1.4	9
12	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, , .	1.7	1
13	098â€¦ Treatment escalation in secondary progressive MS identified clinically and algorithmically in relapsing remitting (RR)MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A131.2-A131.	0.9	0
14	To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 65, 104014.	0.9	17
15	Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 220-231.	1.4	55
16	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	1.4	11
17	Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 52-60.	1.4	41
18	Interpretation of Brain Volume Increase in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 401-407.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	1.4	3
20	Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis. <i>Diagnostics</i> , 2021, 11, 464.	1.3	9
21	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	15
22	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.5	41
23	Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102778.	0.9	7
24	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e869-e880.	1.5	15
25	Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
26	The effectiveness of natalizumab vs fingolimod – A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	0.9	8
27	Age-related magnetic susceptibility changes in deep grey matter and cerebral cortex of normal young and middle-aged adults depicted by whole brain analysis. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 3906-3919.	1.1	16
28	Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103104.	0.9	23
29	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	2.7	8
30	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.	0.3	9
31	Validating atlas-based lesion disconnectomics in multiple sclerosis: A retrospective multi-centric study. <i>NeuroImage: Clinical</i> , 2021, 32, 102817.	1.4	4
32	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.5	54
33	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2001-2013.	1.4	9
34	Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis. <i>Diagnostics</i> , 2021, 11, 2230.	1.3	2
35	The influence on long-term progression of multiple sclerosis - brighter days ahead?. <i>Neurologie Pro Praxi</i> , 2021, 22, 40-44.	0.0	0
36	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	1.4	52

#	ARTICLE	IF	CITATIONS
37	Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000010991.	1.5	6
38	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102534.	0.9	14
39	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. <i>JAMA Neurology</i> , 2020, 77, 1496.	4.5	21
40	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. <i>Journal of Clinical Lipidology</i> , 2020, 14, 675-684.e2.	0.6	8
41	Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102543.	0.9	13
42	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1398.	4.5	21
43	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24
44	Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642097522.	1.5	5
45	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	3.7	32
46	Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis. <i>BioMed Research International</i> , 2020, 2020, 1-6.	0.9	13
47	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.	4.9	219
48	Characterizing vocal tremor in progressive neurological diseases via automated acoustic analyses. <i>Clinical Neurophysiology</i> , 2020, 131, 1155-1165.	0.7	18
49	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	24
50	Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732097213.	0.5	9
51	Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 820.	1.1	16
52	Lifespan normative data on rates of brain volume changes. <i>Neurobiology of Aging</i> , 2019, 81, 30-37.	1.5	40
53	Brain volumetric correlates of dysarthria in multiple sclerosis. <i>Brain and Language</i> , 2019, 194, 58-64.	0.8	16
54	Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study. <i>Journal of Clinical Neuroscience</i> , 2019, 65, 28-33.	0.8	16

#	ARTICLE	IF	CITATIONS
55	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	0.9	71
56	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	0.9	35
57	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	3.8	336
58	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	1.4	55
59	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 541-553.	1.4	32
60	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2018, 388, 87-93.	0.3	7
61	Establishing pathological cut-offs for lateral ventricular volume expansion rates. <i>NeuroImage: Clinical</i> , 2018, 18, 494-501.	1.4	26
62	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [<i>Mult. Scler. Relat. Disord.</i> (2017)]. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 166.	0.9	0
63	Management of multiple sclerosis patients in central European countries: current needs and potential solutions. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641875918.	1.5	17
64	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 105-108.	0.9	22
65	The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018, 28, 328-337.	1.0	4
66	Cognitive clinical-radiological paradox in early stages of multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 81-91.	1.7	26
67	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	1.4	37
68	Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1617-1626.	1.4	36
69	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. <i>NeuroImage: Clinical</i> , 2018, 17, 444-451.	1.4	58
70	Characteristics of motor speech phenotypes in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 62-69.	0.9	58
71	Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 242-252.	1.4	39
72	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 51-61.	1.4	39

#	ARTICLE	IF	CITATIONS
73	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	1.4	30
74	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	0.9	49
75	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	4.9	134
76	Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2017, 38, 1079-1086.	1.2	29
77	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study. <i>Journal of Neuroimaging</i> , 2017, 27, 620-629.	1.0	20
78	MyA mRNA decrease preceding NA detection in IFN β -treated MS patients. <i>Brain and Behavior</i> , 2017, 7, e00644.	1.0	1
79	Serum lipid profile changes predict neurodegeneration in interferon- β 1a-treated multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2017, 58, 403-411.	2.0	43
80	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.	1.5	38
81	Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. <i>Journal of Neuroimmunology</i> , 2017, 313, 89-91.	1.1	8
82	Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2017, 15, 769-779.	1.4	48
83	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	1.4	18
84	Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. <i>European Journal of Neurology</i> , 2017, 24, 292-301.	1.7	38
85	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	3.7	94
86	Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients. <i>BMC Neurology</i> , 2017, 17, 145.	0.8	10
87	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1423-1437.	0.9	25
88	Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFN β . <i>PLoS ONE</i> , 2017, 12, e0169957.	1.1	1
89	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309690.	0.9	90
90	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	3.7	281

#	ARTICLE	IF	CITATIONS
91	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 729-736.	1.7	21
92	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	0.9	63
93	Comparative efficacy of first-line natalizumab vs IFN- β or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 102-115.	0.8	33
94	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 777-793.	1.4	126
95	Reliable measurements of brain atrophy in individual patients with multiple sclerosis. <i>Brain and Behavior</i> , 2016, 6, e00518.	1.0	58
96	Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.6	18
97	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. <i>Neuron</i> , 2016, 92, 333-335.	3.8	24
98	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	2.8	158
99	Alemtuzumab long-term immunologic effect. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e194.	3.1	65
100	A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1709-1718.	1.4	69
101	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. <i>Multiple Sclerosis Journal</i> , 2016, 22, 770-781.	1.4	37
102	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	1.4	34
103	Neuromyelitis optica (Devic's disease) - a rare demyelinating disease. <i>Medicína Pro Praxi</i> , 2016, 13, 43-46.	0.0	0
104	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	2.8	143
105	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	1.4	249
106	Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 31-45.	1.5	134
107	Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β 1a. <i>European Journal of Neurology</i> , 2015, 22, 1113-1123.	1.7	25
108	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	4.5	100

#	ARTICLE	IF	CITATIONS
109	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2015, 56, 2010-2018.	2.0	45
110	Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. <i>American Journal of Neuroradiology</i> , 2015, 36, 1457-1464.	1.2	13
111	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	3.7	162
112	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	1.4	36
113	Neuromyelitis Optica Spectrum Disorders – Retrospective Analysis of Clinical and Paraclinical Findings. <i>Ceska A Slovenska Neurologie A Neurochirurgie</i> , 2015, 78/111, 72-77.	0.0	2
114	MRI correlates of disability progression in patients with CIS over 48 months. <i>NeuroImage: Clinical</i> , 2014, 6, 312-319.	1.4	39
115	Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. <i>Journal of the Neurological Sciences</i> , 2014, 347, 229-234.	0.3	8
116	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. <i>Journal of Neuroimmunology</i> , 2014, 273, 58-64.	1.1	21
117	A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility. <i>Genes and Immunity</i> , 2014, 15, 126-132.	2.2	26
118	Complement activation in patients with neuromyelitis optica. <i>Journal of Neuroimmunology</i> , 2014, 274, 185-191.	1.1	54
119	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 424-433.	1.2	14
120	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 859-864.	0.9	35
121	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. <i>Journal of Neurology</i> , 2014, 261, 1735-1744.	1.8	45
122	Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, S42-S48.	0.6	12
123	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , 2013, 263, 121-127.	1.1	14
124	Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. <i>Genes and Immunity</i> , 2013, 14, 244-248.	2.2	18
125	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. <i>Radiology</i> , 2013, 268, 831-841.	3.6	145
126	Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years. <i>American Journal of Neuroradiology</i> , 2013, 34, 1931-1939.	1.2	90

#	ARTICLE	IF	CITATIONS
127	Lipid profiles are associated with lesion formation over 24 months in interferon- β treated patients following the first demyelinating event. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1186-1191.	0.9	114
128	Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-8.	0.4	9
129	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. <i>PLoS ONE</i> , 2013, 8, e53996.	1.1	68
130	Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2012, 33, 1573-1578.	1.2	133
131	Restless legs syndrome in Czech patients with multiple sclerosis: An epidemiological and genetic study. <i>Sleep Medicine</i> , 2012, 13, 848-851.	0.8	38
132	Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 940-946.	0.6	18
133	Corpus Callosum Atrophy – A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study. <i>European Neurology</i> , 2012, 68, 23-27.	0.6	32
134	Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study. <i>PLoS ONE</i> , 2012, 7, e50101.	1.1	73
135	Early predictors of non-response to interferon in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2012, 126, 390-397.	1.0	22
136	Clinical correlates of grey matter pathology in multiple sclerosis. <i>BMC Neurology</i> , 2012, 12, 10.	0.8	55
137	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. <i>Journal of Neuroimmunology</i> , 2011, 236, 76-80.	1.1	12
138	Multiple Sclerosis and the Accumulation of Iron in the Basal Ganglia: Quantitative Assessment of Brain Iron Using MRI T ₂ * Relaxometry. <i>European Neurology</i> , 2010, 63, 136-143.	0.6	50
139	Patients' Stratification and Correlation of Brain Magnetic Resonance Imaging Parameters with Disability Progression in Multiple Sclerosis. <i>European Neurology</i> , 2009, 61, 278-284.	0.6	10
140	Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 965-976.	1.4	77
141	Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. <i>Lancet Neurology</i> , The, 2009, 8, 1111-1119.	4.9	233
142	Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2009, 282, 112-119.	0.3	84
143	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet</i> , The, 2008, 372, 1463-1472.	6.3	457
144	Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 407-414.	0.9	73

#	ARTICLE	IF	CITATIONS
145	Detection of Cortical Lesions is Dependent on Choice of Slice Thickness in Patients with Multiple Sclerosis. <i>International Review of Neurobiology</i> , 2007, 79, 475-489.	0.9	25
146	Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. <i>Clinica Chimica Acta</i> , 2004, 348, 147-154.	0.5	22